3SBio obtains ex-China global rights to Apexigens anti-TNF mAb technology 3SBio Inc.

3SBio obtains ex-China global rights to Apexigen’s anti-TNF mAb technology 3SBio Inc., , a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody technology. 3SBio acquired the China privileges from Apexigen in 2006 previously. 3SBio's anti-TNF mAb, designated SSS07, has completed pre-clinical assessment and demonstrated higher potency compared to the best-known available TNF inhibitors, including infliximab and adalimumab, potentially improving treatment options for patients with rheumatoid arthritis and other inflammatory diseases.The DSMB found no safety issues that warranted any change in the carry out of the trial.’ General, thirty-eight individuals have already been dosed in two trials. By calendar year end, it is anticipated that you will have a database of more than 200 dosed patients.’.

Almost 62 percent of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study Drugs to take care of cardiovascular conditions best the list in both use and cost for public drug applications Almost two-thirds of Canadians age 65 and older surviving in the community in 6 provinces are using five or even more classes of prescription medications, according to a report released today by the Canadian Institute for Health Information .